Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In a phase 2 trial, once-monthly dosing produced significant weight loss at 52 weeks: 12.3% to 16.2% in patients with obesity without diabetes ( vs 2.5% with placebo), and 8.4% to -12.3% in those with obesity and type 2 diabetes ( vs 1.7% with placebo)
The detected correlation may alternatively stem from unmeasured variations in patients baseline vascular health, advanced metabolic severity, or underlying diabetic complications, rather than a direct cellular effect of the GLP-1 molecules themselves
A separate study on liraglutide - an earlier GLP-1 medication - found that it actually increased bone formation by 16% and reduced total bone mineral content loss compared to a control group during a weight maintenance phase after caloric restriction
With the U.S
Without a disclosed ingredient list, a complete independent safety assessment isn't possible from the outside
